Evaluation of drug interactions and their impact on virological failure of people living with HIV/AIDS over 50 years of age / Avaliação das interações medicamentosas e seu impacto no fracasso virológico de pessoas vivendo com HIV/AIDS acima de 50 anos de idade

Mauricio Fernando Favaleça, Márcio Cesar Reino Gaggini, Wilson Luis de Oliveira, Nilton Cesar Pezati Boer

Abstract


The discovery of the antiretroviral therapy (ART) increased life expectancy of people living with HIV (PLHIV). This chronic condition was associated with other diseases with a higher risk of multiple drug use and drug interactions. Drug interactions can cause therapy failures and side effects. This cross-sectional study was carried out in three specialized clinics located in the northwestern of the state of São Paulo from September to December 2019, and evaluated the potential drug interactions in PLHIV and its impact on virological failure. PLHIV aged 50 years or older were included, using ART and other drugs for more than one year and viral load tests in the last 6 months. The data were obtained through a structured questionnaire and medical records. The interactions were analyzed by the Liverpool drug interaction database. The virological failure was defined as two exams of viral loads above 200 copies/ml. We performed a descriptive analysis of the results. Among the 113 people included in the study, 43.36% acquired the virus after the age of 50 and 61.95% reported had never stopped using ART. There were comorbidities (89.38%), the main ones: arterial hypertension (47.79%), diabetes (20.35%) and depression (17.70%). The drug interactions appeared in 74.34% of the respondents and 7.08% presented contraindicated interactions. The drugs involving the central nervous system were responsible for most interactions (47.58%), followed by antihypertensive drugs, hypoglycemic drugs and statins. Protease inhibitors and non-nucleoside reverse transcriptase inhibitors showed a higher number of interactions. Only three individuals (2.65%) showed virological failure, two of which presented adherence failure. Drug interactions were very prevalent among individuals with HIV/AIDS over 50 years of age and these interactions have the potential to change mainly the comedication concentration and have no significant impact on virological failure.


Keywords


HIV infections, aging, anti-retroviral agents, polypharmacy, drug interactions.

Full Text:

PDF

References


Piot P, Quinn TC. Response to the AIDS Pandemic – A global health model. N Engl J Med. 2013; 368: 2210-2218. DOI: 10.1056/NEJMra1201533

Siddiqi AE, Hall HI, Hu X, Song R. Population-Based Estimates of Life Expectancy After HIV Diagnosis: United States 2008-2011. J Acquir Immune Defic Syndr 2016; 72(2):230-236. DOI: 10.1097/QAI.0000000000000960

Joint United Nations Programme on HIV/AIDS/UNAIDS. Estatísticas. [cited 2020 Sept. 26]. Available from: https://unaids.org.br/estatisticas.

Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis. Boletim Epidemiológico de HIV/AIDS 2019. [cited 2020 Sept. 26]. Available from: http://www.aids.gov.br/pt-br/pub/2019/boletim-epidemiologico-de-hivaids-2019

Benzaken AS, Pereira GFM, Costa L, Tanuri A, Santos AF, Soares MA. Antiretroviral treatment, government policy and economy of HIV/AIDS in Brazil: is it time for HIV cure in the country?. AIDS Res Ther. 2019;16(1):19. DOI:10.1186/s12981-019-0234-2

Smit M, Smit C, Geerlings S. Changes in First-Line cART Regimens and Short-Term Clinical Outcome between 1996 and 2010 in The Netherlands. PLoS One. 2013;8:e76071. DOI: 10.1371/journal.pone.0076071

Courlet P, Livio F, Guidi M, Cavassini M, Battegay M, Stoeckle M, et al. Swiss HIV Cohort Study, Polypharmacy, Drug–Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV, Open Forum Infectious Diseases, 2019 Dec;6(12). DOI: 10.1093/ofid/ofz531

Gebo KA. Epidemiology of HIV and response to antiretroviral therapy in the middle aged and elderly. Aging Health. 2008; 4:615-627. DOI: 10.2217/1745509X.4.6.615

Maschio MBM, Balbino AP, Souza PFR de, Kalinke LP. Sexualidade na terceira idade: medidas de prevenção para doenças sexualmente transmissíveis e AIDS. Rev. Gaúcha Enferm [Internet]. 2011 Set [cited 2019 Jun 09];32(3):583-589. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1983-14472011000300021& lng=en. DOI: 10.1590/S1983-14472011000300021.

Schmid GP, Williams BG, Garcia-Calleja JM, et al. The unexplored story of HIV and ageing. Bull World Health Organ. 2009;87(3):162-162A. DOI:10.2471/BLT.09.064030

Cardoso SW, Torres TS, Santini-Oliveira M, Marins LMS, Veloso VG, Grinsztejn B. Aging with HIV: a practical review. Braz J Infect Dis [Internet]. 2013 ago [cited 2019 Jun 9];17(4):464-479. Available from: http://www.scielo.br/scielo.php?script=sci_ arttext&pid=S1413-86702013000400013&lng=en. DOI: 10.1016/j. bjid.2012.11.007.

Nardelli GG, Gaudenci EM, Silveira RE, Garcia LAA, Malaquias BSS, Santos AS. Knowledge about HIV/AIDS in older adults using the services of Family Health Strategy. Rev. Soc. Bras. Med. Trop. [Internet]. 2019 [cited 2020 Sep 29];52:e20180355. Available from: http://www.scielo.br/scielo.php?script=sci_ arttext&pid=S0037-868220190001006 53&lng=en. Epub May 16, 2019. DOI: 10.1590/0037-86820355-2018.

Gleason LJ, Luque AE, Shah K. Polypharmacy in the HIV-infected older adult population. Clin Interv Aging. 2013; 8:749–763. DOI: 10.2147/CIA.S37738

Marzolini C, Back D, Weber R, Furrer H, Cavassini M, et al. Ageing with HIV: medication use and risk for potential drug–drug interactions. Journal of Antimicrobial Chemotherapy. 2011: 66: 2107–2111. DOI: 10.1093/jac/dkr248

Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância, Prevenção e Controle das Infecções Sexualmente Transmissíveis, do HIV/Aids e das Hepatites Virais. Protocolo Clínico e Diretrizes Terapêuticas para Manejo da Infecção pelo HIV em Adultos. Brasília: 2018.

Evans-Jones JG, Cottle LE, Back DJ, Gibbons S, Beeching NJ, Carey PB, et al. Recognition of Risk for Clinically Significant Drug Interactions among HIV-Infected Patients Receiving Antiretroviral Therapy, Clinical Infectious Diseases, 2010;10(15):1419-1421. DOI: 10.1086/652149

Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, et al. Swiss HIV Cohort Study. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther. 2010;15(3):413-23. DOI: https://10.3851/IMP1540.

University of Liverpool. HIV Drug Interactions. [cited 2019 Jun 9]. Available from: https://www.hiv-druginteractions.org.

Holtzman C, Armon C, Tedaldi E, Chmiel JS, Buchacz K, Wood K, Brooks JT et al. Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population. J Gen Intern Med. 2013:28(10):1302-10.DOI: 10.1007/s11606-013-2449-6

Garbin CAS, Gatto RCJ, Garbin AJI. Adesão à terapia antirretroviral em pacientes HIV soropositivos no Brasil: uma revisão da literature. Arch Health Invest. 2017: 6(2):65-70. DOI: 10.21270/archi.v6i2.1787

Rocha GM, Machado CJ, Acurcio FA, Guimarães MDC. Monitorando a adesão ao tratamento anti-retroviral no Brasil: um desafio urgente. Cad. Saúde Pública [Internet]. 2011 [cited 2002 Sep 29]; 27 (Suplemento 1): s67-s78. Disponível em: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2011001300008 &lng=es. DOI: 10.1590/S0102-311X2011001300008.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. [cited 2020 Aug 27]. Available from: https://clinicalinfo.hiv.gov/sites/default/files/inline-files/AdultandAdolescentGL.pdf.

Justice AC, Gordon KS, Skanderson M, Edelma EJ, Akgün KM, Gibert CL, et al. Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. AIDS. 2018: 32(6):739-749. DOI: 10.1097/QAD.0000000000001 756

Devanathan AS, Anderson DJC, Cottrell ML, Burgunder EM, Saunders AC, Kashuba ADM. Contemporary Drug-Drug Interactions in HIV Treatment. Clin Pharmacol Ther. 2019:105(6):1362-1377. DOI: 10.1002/cpt.1393.

Secoli SR, Figueras A, Lebrão ML, Lima FD, Santos JLF. Risk of Potential Drug-Drug Interactions among Brazilian Elderly: a population-based, cross-sectional study. Drugs Aging. 2010:759-770. DOI: 10.2165/11538460-000000000-00000

Buchacz K, Baker RK, Palella Jr FJ, Shaw L, Patel P, Lichtenstein KA, et al. Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. Antivir Ther. 2013;18(1):65–75. DOI: 10.3851/IMP2450

Nachega JB, Hsu AJ, Uthman OA, Spinewine A, Pham PA. Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. AIDS. 2012;26(Suppl 1):S39–53. DOI: 10.1097/QAD.0b013e32835584ea.

Greene M, Steinman MA, McNicholl IR, Valcour V. Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. J Am Geriatr Soc. 2014;62(3):447-53. DOI: 10.1111/jgs.12695.

McCluskey SM, Siedner MJ, Marconi VC. Management of Virologic Failure and HIV Drug Resistance. Infect Dis Clin North Am. 2019;33(3):707-742. DOI: 10.1016/j.idc.2019.05.004.

Nettles, RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA. 2005;293(7):817-829. DOI:10.1001/jama.293.7.817.

Helou E, Shenoi S, Kyriakides T, Landry ML, Kozal M, Barakat LA. Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study. J Int. Assoc Provid AIDS Care. 2017;16(3):261-266. DOI:10.1177/2325957416680028.

Peyriere H, Eiden C, Macia JC, Reynes J. Antihypertensive Drugs in Patients Treated with Antiretroviral. The Annals of Pharmacotherapy, 2012; 46:703-709. DOI 10.1345/aph.1Q546

Campanha Angela Maria, Ravagnani Beatriz, Milhorança Igor André, Bernik Márcio Antonini, Viana Maria Carmen, Wang Yuan-Pang et al . Benzodiazepine use in Sao Paulo, Brazil. Clinics [Internet]. 2020 [cited 2020 Nov 22] ; 75: e1610. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-593220200001 0024/7&lng=en. DOI: 10.6061/clinics/2020/e1610.

Qureshi Shahab. Drug Interactions with Antiretroviral Therapy (ART). Medscape, 2020. [cited 2020 Oct 05]. Available from: https://emedicine.medscape.com/article/2039809 -overview#a2.

Altena E, Baglioni C, Espie CA, Ellis J, Gavriloff D, Holzinger B, et al. Dealing with sleep problems during home confinement due to the COVID-19 outbreak: Practical recommendations from a task force of the European CBT-I Academy. J Sleep Res. 2020: 29(4):e13052. DOI: 10.1111/jsr.13052.

Park-Wyllie LY, Levine MA, Holbrook A, Thabane L, Antoniou T, Yoong D, et al. Outcomes of Dosage Adjustments Used to Manage Antiretroviral Drug Interactions, Clinical Infectious Disease, 2007:45(7):933–936. DOI: 10.1086/521252




DOI: https://doi.org/10.34119/bjhrv4n1-082

Refbacks

  • There are currently no refbacks.